A lot of pharmaceutical companies spend millions of dollars trying to get their drug approved in India. And still, many of them fail. The thing is, the Indian drug approval process is strict, and small mistakes are made at the wrong stage.

The delays and rejections usually come from basic gaps, unclear documentation, weak CTD structure, or missed compliance steps. These are not big errors, but they cost months or even years.

In this guide, we’ll break down the complete new drug approval process in India, the common mistakes that delay approvals, and finally the important steps after approval to avoid license suspension.

Understanding the New Drug Approval Process in India

In India, drug approvals are governed by the Central Drugs Standard Control Organization (CDSCO) under the Drugs and Cosmetics Act. The approval journey typically follows eight core steps:

1. Drug identification
2. CTD dossier preparation
3. Application submission
4. Clinical trials
5. CDSCO technical evaluation
6. Site inspection
7. Marketing or import license grant
8. Post-marketing surveillance

Every step matters, but one step decides the fate of your application early on, CTD dossier preparation.

Step 1: Drug Identification and Classification

Before anything else, a company must clearly identify what type of drug it is submitting.

In India, drugs are broadly classified into three categories:

• New Drug: A molecule that has never been approved or marketed in India.
• Fixed-Dose Combination (FDC): A new combination of two or more approved drugs in a fixed ratio.
• Investigational New Drug (IND): A molecule still under research or clinical trials and not yet approved for marketing.

Once the drug category is identified, the rest of the process mostly remains the same. If your drug is already approved in the US, Europe, or Japan, you may qualify for a partial or full clinical trial waiver under Rule 122A. However, this depends on CDSCO and SEC decisions.

Step 2: Preparing the CTD Dossier

The Common Technical Document (CTD) is the backbone of drug approval in India. It has five modules, each serving a specific purpose:

Module 1: Regional Administrative Information: This includes India-specific documents such as:

• Form 44
• Treasury challan and fees
• Proposed labels for the Indian market

Module 2: Summaries: This module summarizes Modules 3, 4, and 5 and includes:

• Drug overview and pharmacological class
• Mode of action
• Quality, non-clinical, and clinical summaries

Module 3: Quality (CMC): This is one of the most critical sections and covers:

• Drug substance and drug product details
• Manufacturing process
• Batch consistency
• Analytical methods
• Stability data

Module 4: Non-Clinical Study Reports: Includes pharmacology, pharmacokinetics, and toxicology data.

Module 5: Clinical Study Reports: Contains clinical efficacy and safety data.

CTD is not just a data dump. Modules 2 and 3 allow room for clear storytelling—explaining why the drug is safe, effective, and reliable. Poorly structured CTDs are the biggest reason for clarification requests and approval delays.

Step 3: Application Submission via SUGAM Portal

Once the CTD is ready:

• Applications are submitted through the SUGAM portal
• Form 44 is filed
• Fees are paid
• A reference number is generated

From this point, the file moves into regulatory evaluation.

Step 4: CDSCO Technical Evaluation

CDSCO evaluates:

• Clinical data
• Safety margins
• Pharmacokinetics
• Manufacturing and GMP compliance

The application is reviewed by the Subject Expert Committee (SEC). If the CTD is unclear or incomplete, additional data requests are raised. This is where timelines stretch unexpectedly.

Step 5: Clinical Trials (If Required)

Clinical trials in India must follow Schedule Y of the Drugs and Cosmetics Act. Key points:

• Trial protocols must be approved by an Ethics Committee
• Trial waivers may apply for drugs approved in regulated markets
• For cancer drugs, vaccines, rare disease therapies, trials are often mandatory

The final decision always rests with the SEC.

Step 6: Site Inspection

CDSCO may conduct site inspections to verify:

• GMP compliance
• Data integrity
• Batch consistency
• Equipment validation
• Ethical trial conduct

Existing GMP approvals from the US or Europe may help, but inspections are still discretionary.

Step 7: Marketing or Import License Grant

Once all requirements are met:

• Form 46 is issued for manufacturing in India
• Form 45 is issued for import licenses

At this stage, the drug is legally approved for the Indian market. But the job is not over.

Step 8: Post-Marketing Surveillance (Often Ignored)

After approval, companies must:

• Monitor real-world adverse events
• Submit periodic safety update reports
• Maintain pharmacovigilance systems
• Report recalls, variations, or safety warnings

Many licenses are suspended after approval due to weak post-market monitoring.

How Chemxpert Helps Companies Stay Ahead?

Managing approvals, competitors, suppliers, and compliance manually is slow and risky. Chemxpert, the leading pharmaceutical market intelligence platform, solves this by bringing everything into one place.

With Chemxpert, companies can:

• Track competitors and their approved products
• See supplier networks and sourcing patterns
• Monitor warning letters issued over the last decade
• Analyze ongoing clinical trials
• Access verified supplier contact information

Instead of guessing, teams can learn from market data and past regulatory outcomes. Chemxpert’s dedicated research team continuously organizes data from regulatory filings, inspections, and global sources, saving companies months of manual work.

If this sounds useful, you can book a free consultation call with Chemxpert experts and see how the platform fits your regulatory and sourcing strategy.

Final Thought

Getting a drug approved in India is not about shortcuts. It’s about clarity, structure, and data-backed decisions.

With the right CTD strategy and the right market intelligence, approvals become predictable, not painful.